August 2022: Research Update

This is August’s research update from the AGITG.


Study Chairs: Dr Andrew Oar and A/Prof Andrew Kneebone

The first patient to achieve a pathological complete response on the MASTERPLAN trial is an outcome worth celebrating! Congratulations to the study team!

With this promising result, we encourage members to refer eligible candidates to the study. The study has currently enrolled 25% of its target number of patients.


Study Chairs: A/Prof Michael Jameson and Prof Stephen Ackland

As funding for SPAR recruitment at Australian sites concludes in December, we urge members to assist in identifying eligible patients in Australia.

To check the eligibility for a potential candidate, please email de-identified details to


Study Chairs: A/Prof Stephen Smith

Congratulations to the LICPIC trial for enrolling more than 90% of their total target recruitment.

The study is six patients away from completing its target patient recruitment. To check patient eligibility, please contact


Study Chairs: Dr Lorraine Chantrill and Dr Sarah Maloney

The NEO-IMPACT team would like assistance in recruiting patients – please refer any eligible candidates to this trial. The study sites are located at Warringah Private Hospital, VIC and Wollongong Hospital and GenesisCare North Shore, NSW.

For questions, contact


Study Chairs: A/Prof Jeanne Tie and Prof Peter Gibbs

Congratulations to the DYNAMIC-III team for reaching 81% of their target accrual across 71 sites globally. We are hopeful that the trial will complete its target by early 2023 at its current pace.

Thank you to everyone for their continuing work on this important study.


Study Chairs: Dr Belinda Lee, A/Prof Jeanne Tie and Prof Peter Gibbs

The DYNAMIC-Pancreas study is aiming to recruit 100 Cohort C (immediate resection) participants by the end of August.

In addition, five sites have yet to recruit to the trial. To refer patients and to check eligibility, please contact